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Abstract
Background: Advance Care Planning is recommended for people with end-stage kidney disease but evidence is
limited. Robust clinical trials are needed to investigate the impact of advance care planning in this population.
There is little available data on cost-effectiveness to guide decision makers in allocating resources for advance care
planning. Therefore we sought to determine the feasibility of a randomised controlled trial and to test methods for
assessing cost-effectiveness.
Methods: A deferred entry, randomised controlled feasibility trial, incorporating economic and process evaluations,
with people with end-stage kidney disease, aged 65 years or older, receiving haemodialysis, in two renal haemodialysis
units in Northern Ireland, UK. A nurse facilitator helped the patient make an advance care plan identifying: a surrogate
decision-maker; what the participant would like to happen in the future; any advance decision to refuse treatment;
preferred place of care at end-of-life.
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Results: Recruitment lasted 189 days; intervention and data collection 443 days. Of the 67 patients invited to
participate 30 (45%) declined and 36 were randomised to immediate or deferred advance care plan groups.
Twenty-two (61%) made an advance care plan and completed data collection at 12 weeks; 17 (47.2%) were
able to identify a surrogate willing to be named in the advance care plan document. The intervention was
well-received and encouraged end-of-life conversations, but did not succeed in helping patients to fully clarify
their values or consider specific treatment choices. There was no significant difference in health system costs
between the immediate and deferred groups.
Conclusions: A trial of advance care planning with participants receiving haemodialysis is feasible and acceptable to
patients, but challenging. A full trial would require a pool of potential participants five times larger than the number
required to complete data collection at 3 months. Widening eligibility criteria to include younger (under 65 years of
age) and less frail patients, together with special efforts to engage and retain surrogates may improve recruitment and
retention. Traditional advance care planning outcomes may need to be supplemented with those that are defined by
patients, helping them to participate with clinicians in making medical decisions.
Trial registration: Registered December 16, 2015. ClinicalTrials.gov Identifier: NCT02631200.
Keywords: Advance care planning, Advance directives, End-of-life care, End-stage Kidney disease, Feasibility studies,
Palliative care, Randomized controlled trial, Renal Dialysis
Background
In 2017, more than 25,000 individuals in the United King-
dom (UK) were receiving haemodialysis for end-stage kidney
disease (ESKD) [1]. This is mirrored worldwide, with over
2.5 million people receiving renal replacement therapy [2].
Patients with ESKD characteristically suffer from a wide
range of co-morbidities, including hypertension, diabetes,
heart failure, chronic pulmonary disease, atrial fibrillation, de-
pression, and dementia [3]. Consequently, they are at high
risk for hospitalisation [4, 5] and earlier death [6, 7]. Never-
theless, many patients with ESKD do not discuss issues such
as cardiopulmonary resuscitation, Intensive Care Unit admis-
sion, withdrawal of dialysis, involvement of specialist pallia-
tive care, end-of-life care, and preferred place of death with
healthcare professionals [8, 9]. Many persons with ESKD also
have unmet palliative care needs [10, 11]. In this context, ad-
vance care planning (ACP) may enable shared decision-
making among patients, their families and healthcare
professionals.
ACP is a process of discussions between a patient, their
family and healthcare professionals to clarify values, treat-
ment preferences and goals of end-of-life care [12]. In a var-
iety of settings, ACP is associated with important benefits,
including reduced hospitalisations increased uptake of pallia-
tive care services, improved quality of life, decreased anxiety
and depression among family members, and care that is
more in keeping with patient preferences [13–17]. Conse-
quently, ACP is widely recommended for patients with
ESKD [18–20]. However, recent systematic reviews found
sparse, low-quality data to support the benefits of ACP in
this population [12, 21]. Robust clinical trials are needed to
investigate the impact of ACP on patient and surrogate
decision-making and emotional burden; enactment of patient
preferences for end-of-life care; recourse to life-prolonging
treatments; and use of palliative care services and hospice
care. There is also little available data on cost-effectiveness to
guide decision makers in allocating resources for ACP [22].
Given that implementation success is heavily influenced by a
complex network of patient, staff, organisational and cultural
factors [23], and following guidance from the UK Medical
Research Council on the evaluation of complex interventions
[24], we tested intervention and research processes related to
ACP for patients with ESKD. This work will inform a larger
scale randomised controlled trial, economic evaluation and
process evaluation of ACP for people receiving haemodialy-
sis. We planned deferred entry for the control group, because
we wanted to gauge whether patients allocated to this group
would be distressed at having to wait for the intervention
once the issue of ACP had been raised with them.
Aim
To determine the feasibility of conducting a deferred
entry randomised controlled trial of ACP with patients
who have ESKD, incorporating an economic evaluation
and mixed methods process evaluation.
Our objectives were to investigate:
 Recruitment, retention and participation rates
 Acceptability of the intervention to patients, their
relatives, and healthcare professionals
 Optimal systems for delivering ACP, including the
recruitment and training of clinical staff to facilitate
ACP
 Effect sizes that might help inform sample-size esti-
mates for a full trial
 Randomisation procedures and participants’
willingness to enter a deferred entry trial
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 The suitability of a twelve-week deferral period and
a nine-month process evaluation
 Suitability and timing of survey instruments and
outcome measures
 Time needed to collect and analyse data
 Estimated resource use and costs of delivering ACP
and methods for assessing costs, benefits and cost-
effectiveness
Methods
Patient and public involvement
At the development stage of the trial, we met with pa-
tient representatives from a local charity, the Northern
Ireland Kidney Patient Association, to discuss the ac-
ceptability of ACP, strategies for implementation, and
the suitability of ACP and trial documentation. The
steering group also included a patient with ESKD, who
was invited to co-design the trial processes.
Trial design
A deferred entry [25, 26], parallel group randomised
controlled feasibility trial in which patients and their
nominated surrogate were allocated in a 1:1 ratio to ei-
ther immediate or deferred entry groups. Participants in
the deferred entry group had outcomes measured con-
temporaneously with the immediate entry group but re-
ceived the intervention 12 weeks after baseline data
collection. This allowed a comparison at 12 weeks be-
tween those who had received the intervention at the be-
ginning of the trial (the immediate group) and those
who had not yet received it (the deferred group), as in a
standard randomised controlled trial (RCT).
Participants and settings
Participants were recruited from two haemodialysis units
in Northern Ireland (NI), UK. Patients were eligible for
the trial if they were English speaking; aged 65 years or
older; with ESKD and receiving haemodialysis, with cap-
acity to understand, retain, and weigh the necessary in-
formation in English and communicate their decisions;
identified by their consultant nephrologist as having ei-
ther worsening symptoms, functional decline, or two or
more co-morbidities; and not expected to die in the next
3 months. Surrogates (a relative or friend identified by
the patient as their nominated surrogate and willing to
represent the patient’s wishes should they lose decision-
making capacity, although without formal power of at-
torney) were eligible if they were aged 18 years or older
and able to read, write, and speak English.
The sampling frame was patients meeting initial cri-
teria (aged 65 or older and receiving haemodialysis) reg-
istered with the participating units. Patients on this list
were screened against the full eligibility criteria by their
nephrologist and a nurse trained as an ACP facilitator.
Eligible patients were approached by their nephrologist
to assess their interest in participating. Interested pa-
tients were given patient information packs for them-
selves and a surrogate. The ACP nurse returned to the
patient 2–7 days later to seek their consent. Consenting
patients were asked if they would like support from an
‘expert patient’ and to involve a surrogate. Surrogates
could contact the research team directly using a dedi-
cated phone number or email address, or a form and
reply-paid envelope. Participating surrogates were asked
to avoid discussing the details of the ACP with the pa-
tient until the research started. Surrogates could be in-
volved with the ACP but not in the research if they
preferred.
Intervention
The intervention was offered in the outpatient units
when the patient attended for haemodialysis. The lead
professionals were seven experienced nurses (with 20–
45 years as registered nurses, all with post-registration
courses in renal nursing, and four with counselling qual-
ifications) working in the two haemodialysis units, who
had volunteered for half-day training as ACP facilitators
offered by a local health and social care trust using ‘Sage
& Thyme’ Communication Skills Training on dealing
with people in distress [27]. Patients were given the op-
portunity to receive support from ‘expert patients’ dur-
ing the ACP process. These were five people with ESKD
who were in receipt of a kidney transplant or on dialysis
and who volunteered for a 2 hour training session deliv-
ered by the team doing the ACP training, focused on un-
derstanding ACP and the role of the expert patient. The
expert patient was available to act as a conversation
partner with patients making an ACP, with support from
an identified ACP nurse. A senior nurse in each unit,
supported by a designated consultant nephrologist, over-
saw the intervention process. Before the trial began, pa-
tients attending for dialysis were handed a flyer with a
brief description of the research telling them that their
doctor or nurse might approach them about this in the
following weeks.
1. Participants were offered the opportunity to
complete a plan by an ACP nurse, who discussed
the process with them using the booklet, “Your life
and your choices: plan ahead,” produced by the NI
Public Health Agency and Macmillan Cancer
Support. At this stage, the ACP nurse asked the
participant to complete the ‘Record of my wishes’
form found in the booklet, intended to help patients
organise their thoughts.
2. One-to-two weeks later, the patient completed an
ACP document (Advance Care Planning Summary)
with the help of the ACP nurse, and a trained
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expert patient who (if the patient wished) provided
peer support at the time of ACP completion and
subsequently by telephone, assisted where necessary
by the ACP nurse.
3. The patient’s surrogate was invited to take part in
the discussion if the patient wished.
4. The ACP document was one recommended for use
throughout NI (“A record of my wishes”, developed
by the NI Palliative and End of Life Care
Implementation Group), which records an Advance
Care Planning Summary, alongside the
identification of a nominated surrogate decision-
maker. The plan set out:
a) What the patient would like to happen in the
future
b) What the patient would not want to happen
c) If it was already made: a record of the presence
and broad content of an advance decision to
refuse treatment (ADRT): a legally binding
statement that allows a patient to refuse specific
medical treatments if they lose capacity [13];
and any do not resuscitate (DNR) decision
document.
d) Preferred place of care at the end-of-life
e) Any special requests
Patients were encouraged to keep the ACP with them
and to make it available to anyone caring for them. A
summary was kept with their medical notes and copied
to their General Practitioner (primary care physician),
and community nursing services. The ACP was reviewed
with the ACP nurse after two and 12 weeks, or if
circumstances changed, or the patient changed their
mind about preferences. Participants in the deferred
entry group were offered the intervention 12 weeks after
baseline data collection, following collection of their 12-
week outcome data.
Outcomes
Outcomes were collected in the same way in the imme-
diate entry and deferred entry groups. All outcomes
were measured by trained research assistants who were
aware of group allocation (Table 1).
i. Quality of life as measured by the Kidney Disease
Quality of Life instrument – Short Form (KDQOL-
36™), a 36-item Likert-type scale where each item is
scored on a range of 0–100 and higher scores re-
flect better quality of life [28].
ii. Degree of cognitive impairment as measured by the
Isaacs Set Test (IST 15) [29].
iii. Degree of anxiety, depression, well-being, function-
ing and risk as measured by the Clinical Outcomes
in Routine Evaluation measure (CORE 34) a 34-
item Likert-type scale scored on a 5-point scale ran-
ging from 0 (not at all) to 4 (most or all the time).
Higher scores indicate greater distress [30]. Mean
scores from reference groups are 1.86 (SD 0.75) for
those referred to psychiatric services and 0.76 (SD
0.59) for the general population [31].
iv. Degree to which the patient felt that they had
shared in decision-making about their care as mea-
sured by the Patient Experience of Shared Decision
Making (SHARED) instrument [32], a ten-item
Table 1 Schedule of trial interventions and assessments
Time
points
Immediate entry Deferred entry
Patienta Surrogate Patienta Surrogate
T1
Baseline
IST 15
CORE 34
KDQOL-36™
SHARED
ACP agreement questionnaire IST 15
CORE 34
KDQOL-36™
SHARED
ACP intervention ACP intervention
T2
2/52
ACP 1st reviewb
CORE 34
SHARED
ACP agreement questionnaire before review CORE 34
SHARED
T3
12/52
ACP 2nd reviewb
CORE 34
KDQOL-36™
SHARED
ACP agreement questionnaire after review CORE 34
KDQOL-36™
SHARED
ACP agreement questionnaire
ACP intervention ACP intervention
T4
24/52
ACP reviewb
CORE 34
KDQOL-36™
SHARED
ACP agreement questionnaire after review
IST 15 Isaacs Set Test, CORE 34 Clinical Outcomes in Routine Evaluation measure, KDQOL-36™ Kidney Disease Quality of Life instrument – Short Form, SHARED
Patient Experience of Shared Decision Making instrument
aPatients in both groups also completed a cost diary during intervention period as part of the economic evaluation
bSurrogate may not be at the review of the ACP with the patient (this is at the patient and/or surrogate’s discretion)
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Likert-type scale ranging from ‘Disagree strongly’ to
‘Agree strongly’. Scores are out of 20, with one
point for ‘Agree’, two for ‘Agree strongly’, and no
points for disagreement. Higher scores indicate
more sharing.
v. Agreement between the patient and surrogate in
terms of the patient’s preferences, measured by
asking the carer (by telephone if they were not
present) to make an independent assessment of the
patient’s preferences in relation to the key
information covered by the ACP intervention (a-e
above), before taking part in the ACP and at two
and 12 weeks post ACP.
vi. An economic evaluation of costs and benefits of the
ACP intervention using data from the following
sources:
a. Electronic hospital admissions data for each
patient
b. Patient completed cost diaries documenting
personal health and social care resource use.
These were paper diaries to be filled in weekly
with printed sections for the patient – with help
from a research assistant if required – to
provide details of formal care (e.g. from a home
care worker) or visits from health care
professionals received in the home; contacts
with community doctors or nurses; use of
hospital or residential services. Patients were
asked to record the number and estimated
length of contacts.
c. Health-related quality of life using the SF-6D
utility measure, derived from the SF-12 (con-
tained within the KDQOL-36™ questionnaire).
d. Staff training costs.
e. Staff intervention time for each patient,
documented by staff delivering ACP.
Sample size
We aimed to recruit 40 patient-surrogate dyads. Assum-
ing 25% attrition, this sample size provided sufficient
numbers to allow feasibility to be estimated [33, 34].
Randomisation
The random allocation sequence was generated by a stat-
istician unconnected with recruitment, using randomisa-
tion software, into blocks of random sizes from two to
eight. Block sizes were concealed from the clinical staff in-
volved in recruitment. Allocations were concealed using
sequentially numbered, opaque, sealed envelopes, held by
a research team member unconnected with recruitment
or data collection. These envelopes were opened sequen-
tially following patient consent and baseline data
collection.
Blinding
Analysis of outcome data was carried out by a statistician
and health economists blinded to allocation. However, it
was not possible to blind patients, their surrogates, or clin-
ical staff to the ACP intervention. Neither was it feasible
in a study with limited resources to blind outcome
assessment.
Analytical methods
Baseline data were analysed using descriptive statistics.
The proportion of patients eligible for inclusion, agree-
ing to participate and completing the study was calcu-
lated along with exact binomial 95% confidence intervals
(CIs). Analysis of covariance was used to compare the
mean difference (and 95% CIs) in outcome variables at
12 weeks between the intervention and control group
adjusting for baseline values [35]. Paired t-tests were
conducted to compare changes in outcome measures
within the immediate entry and deferred entry groups.
Statistical analyses were conducted using STATA SE
software, v14.0 [36].
Economic analysis
A cost-consequence analysis was undertaken alongside
the randomised trial.
We tabulated the mean per patient volume of health-
system resource use (healthcare activity) and mean costs
per patient. The difference in costs between groups at
12 weeks was calculated. Standard deviations and 95%
CI were used to describe precision estimates. Unit costs
were informed by NHS 2017/18 reference costs and
market rates. Costs are presented in 2018 Great Britain
Pounds sterling (£) and discounting was not applied.
The mean preference-based quality of life (utility) for
ea13-ch group was calculated at 12 weeks, using UK tar-
iffs for the SF-6D, and adjusted for baseline values. Miss-
ing data were clearly reported, and complete case
analysis used in the first instance. To assess uncertainty
in utility estimates, a sensitivity analysis imputing the
last value carried forward (if appropriate) was under-
taken. Quality adjusted life years (QALYs) were calcu-
lated in a similar fashion for each group. STATA SE
software (v14.0) was used for the economic analysis and
reporting was consistent with the Consolidated Health
Economic Evaluation Reporting Standards (CHEERS)
checklist [37]. As it is unclear whether a cost per QALY
framework is appropriate for decision making about in-
terventions near the end of life, costs and outcomes were
not aggregated into a cost-effectiveness ratio for this
feasibility study.
Process Evaluation
The process evaluation was informed by the findings of
a realist review on implementation of ACP with patients
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with ESKD [23]. In relation to the trial, this was a
mixed-methods sequential explanatory approach in
which the qualitative data are collected after the quanti-
tative data to help explain how the quantitative results
have come about [38]. Research assistants observed staff
training for ACP. They also developed a process map
[39] of the personnel and systems involved in managing
ACP with help from key nursing and medical staff who
had delivered the intervention from the unit recruiting
the majority of participants. Research assistants met with
medical and nursing staff who had delivered the inter-
vention. These staff described in detail their real-world
experience of implementation, outlining all the necessary
steps for delivering ACP in practice. Qualitative data
was collected from those delivering and making ACP,
using a semi-structured guide, to elicit their experience
of ACP (what they hoped ACP would achieve; their con-
cerns and feelings) and their views on barriers and facili-
tators of implementation (the written materials used;
what helped or hindered; what could be done better).
We convened focus groups with four “Sage and Thyme”
ACP trainers, and three ACP nurses. We also inter-
viewed four nephrologists, six patients and five surro-
gates. Interviews and focus groups were digitally
recorded and transcribed verbatim. Each piece of inter-
view and other data was coded in relation to the initial
theory derived from the realist review to allow indexing
and retrieval in a suitable database. The qualitative data
were reviewed by members of the research team search-
ing for configurations that support, contradict and link
theory, seeking to explain outcomes.
Ethical approval
Ethical approval was provided by the Office for Research
Ethics Committees, Northern Ireland. REC reference:
16/NI/0043; Protocol number: B16/06; IRAS project ID:
193402. All participants gave written informed consent.
ClinicalTrials.gov Identifier: NCT02631200. The trial ad-
heres to CONSORT guidelines for randomised pilot and
feasibility trials [40].
Results
Recruitment and time needed to collect and analyse data
The research took place between December 2016 and
August 2018. Recruitment lasted 189 days, with an inter-
vention and data collection period of 443 days. Patients
identified from electronic records as meeting initial re-
cruitment criteria numbered 120. Of these, 99 were
screened against the full eligibility criteria by their neph-
rologist and a nurse trained as an ACP facilitator, and
32/99 were excluded: seven lacked mental capacity; six
were sight or hearing impaired; six had a recent acute ill-
ness or decline; four had less than 3 months life expect-
ancy; two had not experienced either worsening
symptoms, functional decline, or two or more co-
morbidities; one had limited English, and for six patients
no reason was given. Sixty-seven of the 99 patients (68,
95% CI 58–77%) were invited to participate and 30
(45%) declined. Of the 24 patients who gave a reason for
non-participation, 11 (46%) objected to ACP; four (17%)
did not want to distress their spouse by raising ACP;
three (13%) did not want the trouble of answering ques-
tions; one did not want to choose a surrogate; and the
remaining five did not disclose specific reasons. Thirty-
seven patients consented to join the trial, with one pa-
tient withdrawing before baseline data collection at T1,
leaving 36 (54% of those invited, 95% CI 41–66%) to be
randomised: 17 to the immediate intervention group and
19 to the deferred intervention group. The planned sam-
ple size was almost reached (Fig. 1).
Retention and participation
Of all 36 participants, 22 (61, 95% CI 44–77%) made an
ACP and completed data collection at T3. In the imme-
diate entry group, 13 received the intervention and com-
pleted data collection at T2 (2 weeks); with 10
completing data collection at T3 (12 weeks). In the de-
ferred group, 18 entered the follow-up period and com-
pleted data collection at T2; with 12 completing data
collection at T3, 9 receiving deferred ACP, and 7 com-
pleting data collection at T4 (24 weeks). Only one pa-
tient chose to involve an expert patient. By T4, 17
patients (47%) remained in the trial and 19 (53%) had
left, 12 of these from the deferred group. Four of these
19 patients had died; six felt physically unable to
complete the questionnaires; one received a transplant;
one felt too anxious about the research process; one left
because of family ill health; and six did not specify a rea-
son for leaving.
Surrogate involvement was low, with 17 of 36 patients
(47.2%) able to formally identify a surrogate willing to be
named in the ACP document, and 10 surrogates fully
participating in the ACP process and providing informa-
tion on their understanding of the patient’s preferences
(Table 2).
Baseline data
Baseline data are presented in Table 3. The groups were
broadly similar with minor imbalances consistent with
randomisation of a small number of participants. All
participants were white British or Irish.
Outcome measures
Outcome measures are presented in Table 4. KDQOL-
36™ scores were commensurate with those of older
adults receiving dialysis in the United States [41]. Be-
tween T1 and T3, KDQOL-36™ scores fell in the imme-
diate group and rose in the deferred group, and these
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changes were statistically significant in the Effects, Bur-
den and SF12 physical subscales. CORE34 scores were
low compared with the general population [30]. They fell
in the deferred group between T1 and T3 but this
change was not statistically significant.
Many patients found the SHARED tool difficult to use
because the baseline measure required them to think of
a time when they had made a decision with a healthcare
professional, and few could identify such an occasion.
Consequently, few completed this measure.
Cost consequence analysis
Admissions data for the study period were readily avail-
able from electronic hospital records at each site. Pa-
tients were able to provide information for the cost
diaries but most did not record data at home and instead
Fig. 1 Flow of participants through the trial
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waited until attending dialysis to report this information
to research assistants. Initially, we recorded these data
weekly but we changed to monthly because so few
events were reported. Clinical staff recorded their time
in minutes spent at each stage of the research and for
the ACP implementation.
Resource use was categorised into ACP intervention costs:
nephrologist and nursing staff time for training and imple-
mentation, and expert patient facilitation time (Table 5); and
health system costs: hospital admissions, formal home care,
GP visits, and residential aged care services (Table 6). The
mean time taken by nephrologists to introduce ACP was 16
min, and nurses 19min. The mean nursing time taken to
deliver the ACP was 74min. Following randomisation, the
average length of stay for those admitted to hospital over 12
weeks was 10 days for the immediate group and 9 days for
the deferred group. There was no statistically significant dif-
ference in health system resource use or costs between the
immediate and deferred group for any cost category.
The mean quality of life (utility) for the immediate
intervention group decreased by 0.01 at 12 weeks, while
it increased by 0.03 for the deferred group. However,
neither change was statistically significant and there was
no significant difference in utility between groups at 12
weeks when adjusted for baseline values (Table 7). A
similar result was observed for QALYs.
Table 3 Baseline characteristics
Description Immediate entry (n = 17) Deferred entry (n = 19) All (n = 36)
Age (years)a 75.6 (6.81) 73.2 (5.01) 74.9 (6.89)
Age range (years) 67–92 65–83
Sex (male) 14 (82%) 16 (84%)
RRT b (years)c 1 (0.5–4.0) 3 (1.0–7.0) 2 (1.0–5.5)
Number of comorbiditiesc 2 (1.0–4.5) 3 (2.0–4.0) 2 (1.0–4.0)
Diabetes 7 (41%) 5 (26%)
Isaac’s Set Testa 31.7 (7.4) 30.6 (6.3) 31.1 (6.7)
CORE34a 0.48 (0.43) 0.75 (0.57) 0.62 (0.52)
KDQOL-36™
Symptomsa 77.1 (18.6) 67.9 (23.1) 72.2 (21.3)
Effectsa 86.8 (12.1) 65.8 (25.6) 75.7 (22.7)
Burdena 45.6 (27.5) 40.8 (30.2) 43.1 (28.7)
SF12 physicala 37.3 (4.8) 30.7 (10.46) 33.8 (8.8)
SF12 mentala 46.8 (10.7) 51.3 (12.4) 49.2 (11.7)
SHARED scorea 11.5 (6.9)e 8.3 (4.1)e 9.3 (5.2)
University degree 5 (29%) 1 (5%)
Household incomed £10–20,000 (£10–60,000) £10–20,000 (£10–70,000)
Renal Unit 1 13 (76%) 16 (84%)
aMean (standard deviation)
bRenal replacement therapy
cMedian (inter-quartile range)
dMedian, reported in increments of £10,000 (range)
eData from 6 patients in immediate group and 13 in deferred group
Table 2 Surrogate participation
Immediate Deferred All participants
Patients 17 19 36 (100%)
Surrogate named in ACP document 10 7 17 (47.2%)
Participated in ACP process 7 3 10 (27.8%)
Did not participate in ACP 3 4 7 (19.4%)
Convergeda 3 0 3 (8.3%)
No convergence 4 3 7 (19.4%)
aConverged = surrogate’s understanding of ACP converged with patient’s on at least one dimension of ACP
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ACP content
Data were available for 17 patients and their surrogates.
No patients reported having made an advance decision to
refuse treatment or a do not resuscitate document. Thir-
teen of 15 patients identified home as their preferred place
of care at the end-of-life. In terms of their preferences for
future treatment, patients were able to speak in broad
terms (for example, that they would like to continue with
dialysis; or that they would not want to be kept alive in a
vegetative state; or that they would wish treatment to con-
tinue even if quality of life was affected) but many were
unable to articulate preferences in specific hypothetical
circumstances. Eight patients were content to trust their
family in conjunction with the medical staff to take deci-
sions in their best interests. Special requests centred on
funeral and religious arrangements.
Agreement between the patient and their surrogate in
terms of the patient’s ACP preferences is presented in
Table 2. We included patients and surrogates who made
an ACP from both immediate and deferred groups. We
considered the surrogate to have converged if their un-
derstanding moved towards the patient’s views on at
least one dimension of ACP. Overall, only ten surrogates
participated fully in ACP. Of these, three converged and
seven did not.
Process evaluation
This section begins with an overview of ACP implemen-
tation as described through process mapping, then pro-
vides detail on the experiences of patients, surrogates
and staff. Trainers are identified as T1, T2 etc.; patients
Table 5 Staff costs to deliver ACP
Resource use category Staff time in minutes (SD) Mean staff costs (SD) Training fees
Nephrologist introducing ACP per patient – completing patients a 16.3 (10.4) £29.34 (18.72)i
Nephrologist introducing ACP per patient – withdrawing patients b 13.8 (8.0) £24.84 (14.4)i
Nurse introducing ACP per patient – completing patients c 19.0 (9.4) £14.30 (7.08)j
Nurse introducing ACP per patient – withdrawing patients d 13.8 (9.6) £10.38 (7.23)j
Nurse delivering ACP per patient e 73.5 (15) £55.33 (11.29)j
Training time per staff participant f 270 £365.26 £80 (n = 10)
Training time per expert patient g 120 £100 £40 (n = 5)
Compensation per expert patient h £50
adata from 11 patients
bdata from 12 patients
cdata from 17 patients
ddata from 20 patients
edata from 13 patients (9 immediate and 4 deferred ACP)
f3 nephrologists and 7 nurses
g5 expert patients
h1 expert patient
iCost per hour, 48-h week of a hospital based medical consultant - £108
jWeighted average of hourly rate of hospital based nurses. ACP Nurse pay bands: one band 7, four band 6, and one band 5 (one nurse was trained but did not
implement ACP) [48]
Table 4 Outcome measure scores at baseline T1 and T3 (including only people who contribute to complete case analysis)
Variable Immediate (n = 10) Deferred (n = 12)
Baseline T1 T3 Within group P Baseline T1 T3 Within group P Adjusted diff in meanb
(95% CI)
ANCOVA P
KDQOL-36™
Symptomsa 81.7 (17.1) 75.4 (13.3) 0.116 71.4 (20.7) 78.3 (19.2) 0.154 −9.3 (−20.7,2.1) 0.103
Effectsa 89.1 (12.8) 78.4 (16.0) 0.024 68.0 (24.1) 73.4 (21.6) 0.084 −12.2 (−23.3,-1.1) 0.033
Burdena 56.9 (19.6) 46.9 (23.8) 0.100 41.7 (23.9) 55.2 (25.7) 0.001 −22.6 (−36.0,-9.1) 0.002
SF12 physicala 38.3 (4.7) 31.5 (9.5) 0.008 33.2 (11.2) 34.9 (13.0) 0.513 −8.4 (−15.8,-1.0) 0.029
SF12 mentala 51.7 (6.2) 53.3 (6.9) 0.608 53.1 (10.7) 52.4 (6.9) 0.816 1.2 (−5.0,7.3) 0.698
CORE34 0.4 (0.4) 0.4 (0.3) 0.293 0.6 (0.3) 0.4 (0.3) 0.01 0.2 (−0.0,0.3) 0.056
SHAREDc 14.5 (7.8) 12.0 (5.7) 0.344 7.8 (4.0) 11.2 (6.0) 0.167 −4.5 (−17.3,8.3) 0.410
aMean (standard deviation)
bANCOVA adjusted for baseline values
cData from 2 patients in immediate group and 6 in deferred group
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as P1, P2; surrogates S1, S2; consultant nephrologists
CN1, CN2; and ACP nurses ACPN1, ACPN2 etc.
Process mapping
This mapped ACP implementation from staff training
through to the second ACP review. It helped reveal the
complexity and challenge of ACP implementation, with
each plan comprising 10 major and 15 minor processes,
about a third of which were patient contacts. ACP
nurses were associated with 21 of those processes and
nephrologists with six (Fig. 2).
Staff training for ACP
Both doctors and nurses took part in half-day training
for ACP with a multidisciplinary group of experienced,
well-prepared trainers. The trainers expressed a thought-
ful and nuanced view of the nature of ACP, embracing
both practical and relational aspects of ACP. Having
multidisciplinary representation from across a renal
team that was already working together was thought to
enhance the training.
‘And I know everybody kind of really, kind of knew
each other. But you had everybody. You had consul-
tants there. You had nurses. You had…everybody
was there to learn. And everybody chatted away.
They talked and gave answers. And they really
motivated to get this rolling, to get to talk to their
patients about advance care planning.’ (T1)
‘So, I think when you get a group who have a focus
on and also have a structure within which they are
going to apply this knowledge, I think that makes a
difference. It makes the training quite different.’ (T2)
Trainers identified challenges in terms of the suitabil-
ity of the venue and staff having opportunity to attend.
‘I suppose it’s just again that staff can actually get to
it… shortages on the wards or in the community and
they can’t actually come to the training.’ (T1)
Despite the insights and preparation of trainers, attend-
ing staff reported that training related to the ACP
process was too brief and too general – focused on com-
munication about prognosis rather than preparations for
delivering ACP – but the training was still helpful in that
it provided an opportunity for reflection and discussion.
‘…it felt much more like an advanced communica-
tion course…but it wasn’t about which I was hoping
to be more about the nuts and bolts, the fundamen-
tals, how do I actually set this up, how do we run it,
how do we keep it going?’ (CN1)
Table 6 Health system resource use and costs
Resource use
category
Immediate
(n = 13)
Deferred (n =
13)
Difference in resource
use
Immediate £
(n = 13)
Deferred £
(n = 13)
Difference in costs£
Mean SD Mean SD Mean 95%CI Mean SD Mean SD Mean 95%CI
Hospital admissions
(length of stay)
10.46 14.05 9.08 10.37 1.38 −8.61 to 11.38 16,769 22,514 14,550 16,626 2219 −13,801 to 18,240
GP practice or GP out
of hours service
2.69 4.33 3.92 4.50 −1.23 −4.80 to 2.34 24.47 54.22 36.37 48.29 −11.91 −53.47 to 29.66
Formal home care 13.08 39.89 6.46 11.02 6.62 −17.07 to 30.30 87.54 238.6 118 244.5 −30.46 − 226 to 165.10
Residential services 0 0 0.23 0.6 −0.23 −0.59 to 0.13 0 0 41.25 102.56 – –
Total 16,881 22,586 14,742 16,639 2139 −13,919 to 18,198
Table 7 Preference-based quality of life scores (utilities) and quality adjusted life years (QALYs)
SF-6D
utility
Immediate (n = 13) Deferred (n = 13)
Baseline (T1) 12 weeks (T3) Baseline (T1) 12 weeks (T3) Difference between groups
Mean SD Mean SD Mean SD Mean SD Meana 95%CI
0.69 0.09 0.68 0.11 0.68 0.15 0.71 0.13 −0.05 −0.15 to 0.05
QALYs Immediate (n = 13) Deferred (n = 13)
12 weeks (T3) 12 weeks (T3) Difference between groups
Mean SD Mean SD Mean 95%CI
0.12 0.07 0.13 0.07 −0.005 −0.06 to 0.06
aDifference between groups adjusted for baseline values
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Patient experiences of ACP
Interviewed patients reported positive responses to ACP
and felt that it had helped them discuss and plan for
their final illness.
‘Yeah, it was fine. We’re just as we are today. I was
absolutely at ease … I thought it was done all right,
like, you know, I was happy enough.’ (P1)
‘I didn’t want to be resuscitated anymore….I
wouldn’t like to spend my last days in a nursing
home.’(P2)
I feel happy enough with it. At least I have dotted
the ‘Is’ and crossed the ‘Ts’. … there was nothing un-
helpful. I mean, the only thing was the withdrawing
care, which I don’t agree with at all under any cir-
cumstances. ….I want to live until I die. (P3)
ACP helped patients clarify their wishes with both staff
and family, and so engendered a sense of relief.
Well, I think it forces you to …. think about it end of
life and anything surrounding that. So, it helped me
concentrate that- it helped me also stimulate a con-
versation with my wife …. I suppose I’m, yeah, more
content with where I am, and… the direction I’m go-
ing. (P4)
‘Probably relieved a wee bit, you know…because it
made my son aware of my wishes….you’re able to
discuss things a bit better, like, you know, with my
family’ (P3)
Patients professed themselves at ease with involving
their relatives in ACP and found this useful to help with
the discussion.
Well, it’s fine (including a relative in making the
ACP). It was fine. I mean, she and I have a great re-
lationship…. And in fact, she had far more ideas
than I had. (P3)
Surrogate experiences of ACP
Surrogates reported that ACP made them more aware of the
patient’s wishes and stimulated family discussions, which re-
duced uncertainty and gave them increased confidence that
they would be able to make appropriate decisions.
‘I thought it’d probably be a good idea because it
sorts things out and maybe decisions could be made
that, that wouldn’t be up to me, you know, that
would probably take some of the onus off me from
having to make some decisions.’ (S1)
Fig. 2 Process map: Advance care planning, Haemodialysis Unit
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‘I was able to tell the children, you know, that if any-
thing happened everything in here is for dad, I
wouldn’t have probably been able to talk to them
about it.’ (S2)
This was the case even when the surrogate was not in
agreement with the patient’s wishes.
‘He said, “Oh I want to be resuscitated as many
times as possible”, and I was like, “What? Why
would you do that?” And he goes, “Because I do.” He
says, “I got a fighting chance,” and I said, “But, you
won’t get a fighting chance because you may come
back not right,” and he says, “But that’s what I want
to be resuscitated,” and I said, “Well your choice.”
Yeah, so that was fine …I have respect for him … I
mightn’t agree with what he wants but that I make
sure that it is done because it’s the way he wants
it.’(S3)
Experiences of ACP nurses and doctors
When discussing ACP with patients, a wide range of
non-medical aspects were covered, such as helping pa-
tients arrange where they would like to die and formu-
lating wills but much less discussion on the dying
process or realistic medical outcomes.
‘So I had a few patients that had been talking about
writing a will but until they actually did this plan,
they haven’t actually…I don’t remember any patient
really focusing on the final days or hours.’ (ACPN1)
‘They were very unrealistic: “Oh yes, I want the full
everything, treatment.” But you might not survive.’
(ACPN2)
On the other hand, ACP could be a useful process for
starting discussions.
‘I think ACP is about beginning the dialogue with
patients about what is it that they would want to
happen in certain circumstances. And sometimes
that’s relatively easy because it’s easy to define
things like dialysis or resuscitation and things.
But other things are not so straightforward…Some
people say I wouldn’t want this if I had a stroke
but you could have a stroke with very minimal
changes or a stroke that was totally incapacitating
so sometimes it’s difficult to get the details right
but I think it’s very helpful in initiating conversa-
tions with people.’ (CN2)
‘…having a dialogue where we explore the wishes
and fears of the patient…’ (CN3)
As indicated by surrogates, ACP was thought to help
relieve families of some of the burden of decision-
making.
‘… what do their loved ones think of the future? Are
we all being reasonably realistic about the expecta-
tions of health for the future of that patient?… a way
of broaching a difficult subject which is really just to
tease out the fact that we all have finite lifespan”
(CN4)
‘It takes the burden off the family, they’re not left in
a visitor’s room having to make a decision … you
have done everything that person would have
wanted, so it would help with the whole grieving
process rather than you’re thinking, I made that de-
cision, and was that the right decision, you know,’
(ACPN3)
Personal impact on staff
Although staff were supportive of ACP, they found it
personally challenging and felt that formal support
should be made available.
‘So, it is a very emotional process for people in-
volved…it is also emotionally draining at times…
[staff should be supported to] discuss their own is-
sues they’ve had or things that have arisen during
the process.’ (CN2)
‘…you’re writing this in the event that something
may happen to you that you can’t voice your own
wishes…And it suddenly made me think what I
would like, what I wouldn’t like, if you’re ever in that
position yourself.’ (ACPN3)
Factors thought to help or hinder ACP
A key issue was the timing of ACP in relation to the pa-
tients’ capacities and stage of disease. Those thought
closest to death and therefore most in need of ACP were
also those least able to engage with the burden of mak-
ing a plan. Consequently, staff believed ACP should be
offered earlier in the disease trajectory.
‘I think I would like to see it introduced at an earlier
stage because as we’ve seen as the trial has pro-
gressed, patients withdrew mainly because they were
sick, and then we had a lot of deaths too during the
study so I think introducing that at an earlier stage
in the patients journey, it’s a better time for staff I
think as well as patients.’ (ACPN1)
Nurses and doctors collaborating effectively was
thought to support a successful process.
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‘…actually it’s useful to have the consultant in-
volved early on, and I think our uptake of the pa-
tients who were interested was slow until the
consultants got involved, so I think the combin-
ation of the nurse involvement and a consultant
together worked, seemed to work well, so that was
a learning point for us.’ (CN4)
It was acknowledged that ACP required a holistic and
individualised approach, matching staff and resources to
the particular needs of the patient.
‘[Patients] varied you know, in terms of like patients
who were here a long time, you know, years, more
than eight or nine and asking patients who were
maybe only starting dialysis, you know, so they’re
very varied in terms of where they are…maybe
[some] were more ready than others.’ (ACPN1)
‘…tailoring written information and tailoring verbal
information is so important…some are comfortable
reading, some are less comfortable reading…giving
written information isn’t a substitute for making sure
that people actually fully understand what they’re
participating in.’ (CN3)
A renal healthcare culture focused on treatment and
cure, together with a societal culture of avoiding discus-
sion of death was thought to hinder staff broaching
prognosis, quality of life issues, and end-of-life care.
‘[Patients are] not always aware that it’s a life-
limiting illness and they do need to think about the
future.’ (ACPN1)
‘I don’t think it’s an area that has got a narrative
around it, it’s not something that people have been
talking about, it’s not part of docu-dramas or it’s not
on soaps about making advance care plans, so it’s a
reasonably foreign concept to patients…concerns per-
haps about the legal basis of it, people are maybe a
wee bit shy…’ (CN3)
Organisational limitations in terms of lack of dedicated
time and facilities were identified as key hindrances to
ACP. In addition the communication infrastructure for
ACP to be disseminated to community healthcare ser-
vices was a concern.
‘…in terms of coming back to implementing it, into
routine practice, it takes time, it takes time to do it
well. It requires recurrent review because the pa-
tients are going to change, their prognosis is going to
change, their feelings are going to change, their
wishes are going to change and you need to be able
to come back to that.’ (CN3)
‘The biggest issue we found was that of time and
finding an appropriate place … to do it … it’s a very
time-consuming thing in trying to fit it into normal
practice…actually relied on us just doing it on our
own time essentially.’ (CN2)
‘I just would want to make a comment about the
dissemination of the plans which is not as straight-
forward as maybe people thought it would be. And
that for the GPs are sent a copy, but the GPs got it
recorded in a system that will not necessarily be
available for everybody in the community to access.’
(ACPN1)
The burdens and benefits of implementing ACP as part of
a trial
Doing ACP in the context of a clinical trial had both
benefits and burdens for clinical staff.
‘Because we’re nurses, and then a time factor as well,
maybe come out of your break earlier, left break
earlier to try and catch up with the documentation,
so it was a time factor.’ (ACPN3)
‘...there seemed to be pages upon pages [of trial docu-
mentation]… (ACPN1)
‘…actually the study made it helpful because you
could tell patients that this was part of a study, that
it wasn’t that you had any particular concerns about
them. And it’s very difficult to gauge end of life in
renal failure patients so it was a nice way to begin
the conversation.’ (CN2)
Discussion
Our study showed that recruitment of patients receiving
haemodialysis and their surrogate decision makers into a
trial of ACP is possible but not without its challenges.
Recruitment was planned to take 3 months but took just
over 6 months. Time needed for recruitment could have
been shortened by more intensive deployment of clinical
staff but this has resource implications. About a third of
patients assessed for eligibility were excluded, and nearly
half of those invited declined to take part. We had antic-
ipated 25% attrition but it reached 39% at 12 weeks and
53% at 24 weeks. This suggests that planning the sample
size for a full trial would require the pool of potentially
eligible patients to be at least three times larger than the
number required for initial participation, and five times
larger than the number required to complete data collec-
tion at 3 months.
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The challenges of recruitment to trials of palliative
care (Boland et al., 2015) and ACP are well known (Sul-
livan, Garner and Dubbert, 2016; Stewart et al., 2018).
Our ratio of recruitment was consistent with that of one
small (Song et al., 2010) and one large trial (Song et al.,
2015) of ACP among dialysis patients in the USA, but
our figures for attrition following consent were higher
than in the larger trial, which reached 30% at 2 months.
This may be because our eligibility criteria meant we
predominantly recruited frailer patients, and indeed, par-
ticipating clinicians recommended approaching patients
earlier in their disease trajectory.
Our study was designed as a deferred entry trial. A de-
ferred entry trial has the advantages of a standard RCT
because outcome data is collected from the deferred
group before they receive the intervention, so allowing a
comparison at that stage between those who have re-
ceived the intervention and those who have not. It is also
thought to encourage participation and reduce distress
because all participants will eventually receive the inter-
vention. A limitation is that this constrains the time at
which the outcome data is collected as this is also the
period that deferred patients must wait [25]. In our case,
neither research assistants nor ACP nurses, nor inter-
view data from participants reported patients being dis-
tressed by the offer of ACP, or by having to wait for the
intervention, suggesting that a deferred entry trial may
be unnecessary. The dialysis unit appears to lend itself
to the ACP process in that it provides the opportunity
for the development of supportive relationships with
staff and regular contact to make an ACP.
Our sample was too small to be able to show differ-
ences in outcome measures between the immediate and
deferred groups. Research assistants reported that pa-
tients were not distressed by the content of the data col-
lection instruments but found the volume of data
collected burdensome. In terms of the timing and fre-
quency of outcome measures, there were minimal differ-
ences between scores at baseline and T2 (2 weeks),
suggesting that these data do not add anything useful.
Outcome measurement at three and 6 months post
intervention may be more likely to capture immediate
and longer-term differences between groups. The SHAR
ED tool proved unsuitable in itself, largely because pa-
tients were inexperienced in shared decision-making,
suggesting that the ACP intervention needs to include
support for developing these skills and that other mea-
sures should be tried to assess shared decision-making
with this population.
Detailed data on staff time spent on ACP related
tasks were collected successfully along with the docu-
mentation of the ACP process. This estimate is prob-
ably conservative, as we did not anticipate all of the
sub-processes of the intervention. Data on hospital
admissions were readily available from routinely col-
lected administrative data.
Fifteen patients – 22% of those approached - refused
to take part in the trial because they objected to ACP or
were concerned that it would distress their spouse, per-
haps reflecting continued misgivings and misunder-
standings about ACP in the UK. Less than half the
patients were able to involve a surrogate and there was a
very small effect on convergence of views on ACP, per-
haps because much ACP content was at a level of broad,
non-specific preferences. This may partly be due to limi-
tations in our intervention, which provided an opportun-
ity for the patient and surrogate to discuss and plan
future preferences but evidently did not succeed in help-
ing patients to fully clarify their values or consider spe-
cific treatment choices. It may also be due to the
inherent difficulty patients experience in imagining both
possible medical conditions and decisions about com-
plex major treatments they have not yet experienced
[42]. Nevertheless, those who did take part were content
to make an ACP, with both patients and surrogates feel-
ing relieved to have done so and reporting reduced anx-
iety and – for surrogates - increased confidence that
they could represent the patient’s wishes, with some pa-
tients saying they would trust family to work with med-
ical staff to take decisions in their best interests. This
may point to focusing ACP interventions on preparation
rather than prediction, preparing patients and surrogates
to participate with clinicians in making the best possible
in-the-moment medical decisions in light of the patient’s
values and goals. Traditional ACP outcomes may need
to be supplemented with those that are defined by pa-
tients, exploring what they wish to achieve through
ACP, such as starting this important conversation with
family and clinical staff, clarifying values, and exploring
the role of the surrogate [42, 43], as measured by instru-
ments such as the ACP engagement survey [44].
Conclusions
A trial of ACP and its associated costs is feasible in pa-
tients receiving haemodialysis (subject to allowance for
challenges in recruitment and retention of patients and
their surrogates) and could provide a reliable estimate of
the effects of ACP and whether this is a good use of re-
sources. Based on recruitment and retention in our
study, if 1200 patients were assessed for eligibility and
invited to participate in a randomised trial, this would
result in 400 being randomised, with 200 (100 in inter-
vention and control groups) available 6 months later to
be analysed for differences in ACP engagement. For ex-
ample, this would give 90% power at the 5% level of sig-
nificance to detect a mean increase of 0.5 on a 5-point
Likert scale using the 15-item Advance Care Planning
Engagement Survey [45]. Given a mortality rate of 10%
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per year [46], 40 participants in each group would be ex-
pected to die during the 2 years after the intervention.
This would give 80% power at the 5% level of signifi-
cance to detect an increase in the proportion of patients
whose wishes were known and respected at the time of
death from 30 to 65% [47]. Shorter follow up for this
outcome would require a larger sample because of the
smaller proportion of deaths among the randomised pa-
tients (for example doubling the sample size would allow
follow up over just 1 year). Widening eligibility criteria
to include younger (under 65 years of age) and less frail
patients, together with special efforts to engage and re-
tain surrogates would probably improve recruitment and
retention. There are just 700 patients being dialysed in 6
units in NI, so recruitment would need to include three
or four larger dialysis units from elsewhere in the UK.
This would increase the generalisability of results and
allow the inclusion of more patients from ethnic
minorities.
Experienced nurses and doctors were able to deliver
ACP on-site to an acceptable standard after training for
only half a day, and with ongoing informal support from
the research team. However, those with less experience
might require more extensive training and formal on-
going support.
A significant proportion (45%) of those invited to par-
ticipate declined. About one third of these appeared to
object to ACP in itself, with the remainder concerned
about the impact on a spouse or the effort involved in
answering research questions. Those who took part in
the process evaluation professed themselves content
with the process, excepting the involvement of expert
patients. Therefore, whilst ACP seems to be acceptable
to most patients in this population, as well as to partici-
pating clinical staff, issues of patient and surrogate un-
derstanding, and burden of research must still be
addressed.
Further, the ACP intervention needs to be developed
to include clarification of patients’ values and prepar-
ation of patients and surrogates to participate in shared
decision-making with clinicians. This in turn has impli-
cations for training and support for staff, which should
be focused on helping them gain confidence in the hu-
man aspects and practicalities of the ACP process. Out-
come measures can be a burden for patients, so these
should be focused on important process-related (identi-
fying a surrogate, clarifying values) and patient-centred
outcomes; as well as measuring preparedness for
decision-making for both patient and surrogate.
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